Vetoquinol wins FDA approval for Felpreva, a quarterly cat treatment
Vetoquinol won FDA approval for Felpreva, a prescription topical parasiticide for cats applied four times a year, with vets able to order in 2027.

Vetoquinol has won FDA approval for Felpreva, a prescription topical parasiticide for cats that is applied just four times a year. The French animal health company describes it as a broad-spectrum treatment built for cats alone, and it has sold the product in the European Union since 2022.
Veterinarians in the U.S. will be able to order Felpreva in 2027, according to the Vetoquinol USA product page. The next scheduled update from the company is its 2026 annual sales release on January 14th, 2027.
Felpreva asks for four doses a year
The U.S. label covers fleas, ticks, mites, roundworms and tapeworms, which puts Felpreva in the same broad-spectrum lane as the monthly cat products it will sit beside on a clinic shelf.
Felpreva treats and prevents fleas for 12 weeks, and it is applied as a topical dose.
It also treats and controls black-legged ticks for 12 weeks. Lone star ticks are covered for 8 weeks, and the label applies to cats 6 months and older that weigh at least 2.2 lb.
"We are excited to bring Felpreva to U.S. veterinarians and cat owners," said Matthieu Frechin, Chairman and CEO of Vetoquinol. "Felpreva takes the complexity out of parasite control for both veterinarians and cat owners by providing a straightforward solution: fewer applications with broad-spectrum treatment and control."
The U.S. label names emodepside, praziquantel and tigolaner as the active ingredients.
Vetoquinol, founded in 1933 and based in Lure, France, has been listed on Euronext Paris since 2006 and employed 2,526 people as of June 30th, 2026, selling medicines for cattle, pigs, dogs and cats across Europe, the Americas and Asia/Pacific.
Rivals dose monthly or every two months
Felpreva enters a feline parasiticide shelf where the big names are dosed more often. Merck's Bravecto Plus for cats combines fluralaner and moxidectin and protects against fleas, ticks and heartworms for 2 months. Zoetis sells Revolution Plus for cats, a monthly selamectin and sarolaner product for cats 8 weeks and older that weigh 2.8 lb or more.
Boehringer Ingelheim's NexGard COMBO for cats is also monthly. It pairs esafoxolaner, eprinomectin and praziquantel, and it is labeled for kittens 8 weeks and older that weigh at least 1.8 lb.
Counted on label intervals, Felpreva needs one-third of the applications a monthly product does. That is 4 a year, against 6 for Bravecto Plus and 12 for the others. On the labels, all three rivals list heartworm prevention, while Felpreva's U.S. page lists fleas, ticks, mites, roundworms and tapeworms.
Cat clinic visits grew while overall visits fell
CATalyst Council data covered in our report on cat vet visits showed cat clinic visits up 2.7% year over year in the third quarter. Overall U.S. clinical visits fell 1.9% in the same period, which makes the cat gain stand out against the wider slide.
Only about 33% of household cats visit a traditional practice each year, says CATalyst Council.
Zoetis, which sells Revolution Plus, said in its third-quarter results that companion animal revenue fell 5% and dogs and cats fell 6%.
Felpreva is a prescription-only product for cats exclusively, in the U.S. as in Europe. Vetoquinol USA says veterinarians can order it in 2027.
Every Felpreva sale runs through a veterinarian.
Source: Vetoquinol via Business Wire
Other News
More stories shaping the pet industry this week. From funding rounds and product launches to regulatory shifts and retail strategy, stay ahead of what's driving the market.
